Modular Medical Appoints David Bosshard as Head of International Operations to Drive Global Expansion of Pivot Insulin Delivery System
PorAinvest
lunes, 6 de octubre de 2025, 8:51 am ET1 min de lectura
MODD--
The appointment comes at a pivotal time as Modular Medical advances its next-generation Pivot insulin delivery system through the U.S. and CE Mark regulatory processes. The company aims to enhance accessibility for underserved diabetes patients worldwide by targeting the $3 billion adult "almost-pumpers" diabetes market [1].
Key highlights of Bosshard's expertise and strategic impact include his success in scaling the Omnipod and launching the YpsoPump with international users, aligning perfectly with Modular Medical's mission to make affordable, intuitive patch pumps accessible worldwide. The company is excited to harness his expertise in launching the Pivot product internationally, as it seeks to access high-growth markets outside the U.S. and evaluate each for direct and indirect distribution opportunities [1].
Modular Medical's mission is to revolutionize insulin delivery with affordable, easy-to-use solutions for the millions of "almost-pumpers" who avoid traditional pumps due to complexity and cost. The Pivot insulin delivery system is not currently cleared for sale by the FDA, but the company is working towards regulatory approvals to expand its market reach [1].
Modular Medical has appointed David Bosshard as Head of International Operations to drive global growth of its Pivot insulin delivery system. Bosshard has two decades of experience scaling tubeless insulin delivery systems across Europe and beyond, including launching Insulet's Omnipod and Ypsomed's YpsoPump. He will leverage his success to position the Company for international growth in the wearable diabetes technology sector, targeting the $3 billion adult "almost-pumpers" diabetes market.
Modular Medical, Inc. (NASDAQ: MODD) has appointed David Bosshard as Head of International Operations to spearhead the global growth of its Pivot insulin delivery system. With two decades of experience in scaling tubeless insulin delivery systems across Europe and beyond, Bosshard will leverage his success in launching Insulet's Omnipod and Ypsomed's YpsoPump to position the company for international growth in the wearable diabetes technology sector [1].The appointment comes at a pivotal time as Modular Medical advances its next-generation Pivot insulin delivery system through the U.S. and CE Mark regulatory processes. The company aims to enhance accessibility for underserved diabetes patients worldwide by targeting the $3 billion adult "almost-pumpers" diabetes market [1].
Key highlights of Bosshard's expertise and strategic impact include his success in scaling the Omnipod and launching the YpsoPump with international users, aligning perfectly with Modular Medical's mission to make affordable, intuitive patch pumps accessible worldwide. The company is excited to harness his expertise in launching the Pivot product internationally, as it seeks to access high-growth markets outside the U.S. and evaluate each for direct and indirect distribution opportunities [1].
Modular Medical's mission is to revolutionize insulin delivery with affordable, easy-to-use solutions for the millions of "almost-pumpers" who avoid traditional pumps due to complexity and cost. The Pivot insulin delivery system is not currently cleared for sale by the FDA, but the company is working towards regulatory approvals to expand its market reach [1].

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios